Special Issue

Imaging of Melanoma and Nonmelanoma Skin Cancer: New Challenges in the Era of Immunotherapy and Precision Oncology

Message from the Guest Editors

Immunotherapy with immune checkpoint inhibitors has been recently introduced as an effective therapeutic option both for malignant melanoma and nonmelanoma skin cancer. Since only 20-40% of patients respond to immunotherapy, in this scenario, several imaging techniques have been applied, such as CT and MRI, with promising results. Furthermore, PET/CT and PET/MRI with 18F-FDG have been utilized to study both tumor biology and metabolism in patients affected by skin cancer undergoing targeted and immunotherapies. In recent years, in vivo PET imaging of biomarkers associated with immunotherapy response (i.e., immuno-PET) is used to assist patients with pre-treatment selection and early identification of treatment resistance. In this Special Issue, we encourage researchers to submit original papers, review articles, or interesting images on morphological and functional imaging approaches in patients affected by skin cancer undergoing immunotherapy and targeted therapy, with a particular emphasis on more innovative and emerging applications (i.e., radiomics, immuno-PET).

Guest Editors Prof. Dr. Luca Filippi

Dr. Barbara Palumbo

Prof. Dr. Orazio Schillaci

Deadline for manuscript submissions closed (31 May 2022)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/99375

Diagnostics Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 diagnostics@mdpi.com

mdpi.com/journal/ diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



diagnostics



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).